Development of low-touch, high-impact adherence solutions through innovation partnerships
In the June issue of ONdrug Delivery magazine, SHL Medical’s Chelsea Williams, Nils Weber, and Gene Rhode Fuensalida Pantig, discuss the potential of collaborative digital health innovation programs toward developing high-impact adherence solutions that harness the power of data.
Here, the authors acknowledge the inherent complexities that exist in the development of pharmaceuticals and digital technologies, emphasizing the absence of a one-size-fits-all approach to generating value from connecting and digitizing treatment modalities. To this end, SHL established the Innovation Partnership Framework, a collaborative approach to the drug delivery innovation process. This enables SHL and its pharma partners to co-develop connected solutions and evaluate different use cases on a smaller scale through an agile approach. Complementing this framework is SHL’s latest connected device technology – the Molly Connected Cap.
The Molly Connected Cap is the most recent addition to SHL’s innovative drug delivery device portfolio. The technology leverages the market-proven Molly modular platform autoinjector and enables connectivity through a compact and retrofittable device cap module. Upon cap removal from the Molly device, the Connected Cap becomes active and relays timestamped data through a smart data transmission hub and to the cloud. Through the Connected Cap and its Innovation Partnership Framework, SHL is in active partnerships with pharma, clinical, R&D, HCP, and patient groups to identify what the value of connectivity means for each segment.
Access the article here and learn how SHL’s latest digital health solution can help drug-device programs toward unleashing the real-world value of connected therapeutics.
